Advanced

A Clinician View and Experience of Proteomic Studies in the Light of Lung Cancer in Japanese Healthcare

Kato, Harubumi; Nishimura, Toshihide; Hirano, Takashi; Nomura, Masaharu; Tojo, Hiromasa; Fujii, Kiyonaga; Kawamura, Takeshi; Mikami, Sayaka; Kihara, Makoto and Bando, Yasuhiko, et al. (2011) In Journal of Proteome Research 10(1). p.51-57
Abstract
In Japan, rising costs have impacted the framework of maintaining an efficient and effective healthcare system. Today, urgent implementation of programs to address this need have led to a rebuilding of the entire approach of medical evaluation and clinical care. Recent developments in clinical proteomics based on mass spectrometry (MS) for identifying, sequencing, and quantifying disease-relevant protein biomarkers is a promising means for optimal drug prescription using biomarker diagnosis. We illustrate in this report our experience with lung cancer cases with various drug therapies evaluated with proteomics studies.
Please use this url to cite or link to this publication:
author
, et al. (More)
(Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
lung cancer, diagnosis and treatment, proteomic study, healthcare
in
Journal of Proteome Research
volume
10
issue
1
pages
51 - 57
publisher
The American Chemical Society
external identifiers
  • wos:000285812000007
  • scopus:79951533736
ISSN
1535-3893
DOI
10.1021/pr100859b
language
English
LU publication?
yes
id
2061689c-3a2b-4e5c-86a5-fde18072ef77 (old id 1869124)
date added to LUP
2011-04-04 13:28:17
date last changed
2017-01-01 04:10:18
@misc{2061689c-3a2b-4e5c-86a5-fde18072ef77,
  abstract     = {In Japan, rising costs have impacted the framework of maintaining an efficient and effective healthcare system. Today, urgent implementation of programs to address this need have led to a rebuilding of the entire approach of medical evaluation and clinical care. Recent developments in clinical proteomics based on mass spectrometry (MS) for identifying, sequencing, and quantifying disease-relevant protein biomarkers is a promising means for optimal drug prescription using biomarker diagnosis. We illustrate in this report our experience with lung cancer cases with various drug therapies evaluated with proteomics studies.},
  author       = {Kato, Harubumi and Nishimura, Toshihide and Hirano, Takashi and Nomura, Masaharu and Tojo, Hiromasa and Fujii, Kiyonaga and Kawamura, Takeshi and Mikami, Sayaka and Kihara, Makoto and Bando, Yasuhiko and Tsuboi, Masahiro and Ikeda, Norihiko and Marko-Varga, György},
  issn         = {1535-3893},
  keyword      = {lung cancer,diagnosis and treatment,proteomic study,healthcare},
  language     = {eng},
  number       = {1},
  pages        = {51--57},
  publisher    = {The American Chemical Society},
  series       = {Journal of Proteome Research},
  title        = {A Clinician View and Experience of Proteomic Studies in the Light of Lung Cancer in Japanese Healthcare},
  url          = {http://dx.doi.org/10.1021/pr100859b},
  volume       = {10},
  year         = {2011},
}